Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07156500

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females, Age ≥18 years at the time of signing informed consent.
  • Diagnosed with type 2 diabetes mellitus (T2DM) for at least 90 days prior to day of screening.
  • Treatment with Diet and Exercise alone at least 90 days prior to day of screening.
  • 7.5% ≤ HbA1c ≤10.5% at screening.

Exclusion criteria

  • Uncontrollable hypertension(with or without antihypertensive treatment) : systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg at screening.
  • Diagnosed or suspected with type 1 diabetes mellitus, special types of diabetes or secondary diabetes.
  • History of significant hematological disorders (e.g., sickle cell disease, hemolytic anemia, myelodysplastic syndrome, etc.) or other conditions causing hemolysis or instability of red blood cells (e.g., malaria, hypersplenism, etc.).
  • Presence of an endocrine disorder or history that may significantly affect bady weight(e.g., Cushing's syndrome, hypothyroidism or hyperthyroidism, except hypothyroidism if thyroid hormone replacement dose has been stable for at least 6 months) ;
  • Severe infection, severe trauma, or moderate-to-major surgery within 4 weeks before screening.
  • Participated in clinical trials of any drug or medical device within 12 weeks prior to screening, and participation in clinical trials is defined as signing informed consent and using investigational drugs (including placebo) or investigational medical devices; Or is still in the trial drug within 5 half-lives (whichever is Longer).

Treatment and study plan

HS-20094 Injection

Drug

HS-20094 injected subcutaneously once weekly

HS-20094 Placebo Injection

Drug

HS-20094 Placebo injected subcutaneously once weekly

Primary outcomes

  1. Change in HbA1c

    Time frame: Week 0 to Week 44

    Change from baseline in HbA1c after 44 weeks of treatment

Secondary outcomes

  1. Proportion of subjects with HbA1c<7.0% and ≤6.5%

    Time frame: Week 0 to Week 44

    Proportion of subjects with HbA1c<7.0% and ≤6.5% after 44 weeks of treatment

  2. Change in FPG

    Time frame: Week 0 to Week 44

    Change from baseline in FPG after 44 weeks of treatment

  3. Change in body weight

    Time frame: Week 0 to Week 44

    Change from baseline in Change in body weight after 44 weeks of treatment

  4. Proportion of subjects with weight loss ≥5% and ≥10%

    Time frame: Week 0 to Week 44

    Proportion of subjects with weight loss ≥5% and ≥10% after 44 weeks of treatment

  5. Change in HbA1c

    Time frame: Week 0 to Week 52

    Change from baseline in HbA1c after 52 weeks of treatment

  6. Proportion of subjects with HbA1c<7.0% and ≤6.5%

    Time frame: Week 0 to Week 52

    Proportion of subjects with HbA1c<7.0% and ≤6.5% after 52 weeks of treatment

  7. Change in FPG

    Time frame: Week 0 to Week 52

    Change from baseline in FPG after 52 weeks of treatment

  8. Change in body weight

    Time frame: Week 0 to Week 52

    Change from baseline in Change in body weight after 52 weeks of treatment

  9. Proportion of subjects with weight loss ≥5% and ≥10%

    Time frame: Week 0 to Week 52

    Proportion of subjects with weight loss ≥5% and ≥10% after 52 weeks of treatment

  10. Incidence and severity of adverse events

    Time frame: Week 0 to Week 52+4 weeks follow-up

    Severity (mild, moderate and severe) is assessed by investigator

Sponsors and collaborators

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Sep 5, 2025
Registry last updated
Sep 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.